The health landscape sees pivots as companies adjust strategies: Bristol Myers and Pfizer offer discounts on Eliquis, Newcastle University's IVF technique prevents genetic diseases, and Juul's ...

Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.

Ovarian Cancer Drugs Market grows as FDA, EMA fast-track advanced-stage therapies, boosting global approvals and innovation. Anurag Tiwari Orion Market Research Pvt Ltd + +91 91798 28694 email us here ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...